Search PubMed⌕ Search

Biomedical subjects

T Ohara

Publications and source records attributed to T Ohara.

At least 199 records · Page 11Linked to original sources
PubMed1986

Isolation and characterization of galactose-binding proteins from new-born mice.

Two galactose-binding proteins were purified from the soluble extracts of new-born mice by affinity chromatography using a column of lactamyl-Sepharose. The molecular masses of their subunits were 15 (galactose-binding protein 15K) and 16 (galactose-binding protein 16K) kDa, and the isoelectric points were 5.3 and 6.8, respectively. These galactose-binding proteins agglutinated formaldehyde-fixed trypsinized rabbit erythrocytes. Hemagglutinating activity was inhibited by galactose-containing saccharides and glycopeptides. N-Acetyllactosamine and asialo-glycopeptides having N-acetyllactosamine at non-reducing termini were found to be the most effective inhibitors so far examined. These results suggest that galactose-binding proteins can recognize lactosaminoglycans on erythrocyte surfaces. The elution patterns of gel filtration by high performance liquid chromatography showed galactose-binding protein 15K to form dimers of identical subunits, galactose-binding protein 16K to be monomeric, and neither to interact with each other under the conditions employed. The results obtained by immuno-blotting with antisera raised against purified galactose-binding proteins and amino acid analyses indicate that galactose-binding proteins 15K and 16K are not identical molecules. The distribution of galactose-binding protein 15K on frozen sections of new-born mice was surveyed by indirect immunofluorescence staining. Galactose-binding protein 15K was found widely distributed on many tissues, and distinct staining was observed in the liver and epidermis but not in the brain of unfixed samples.

Amino Acids↗
PubMed1986

[Effect of hemodialysis on left and right ventricular function--evaluation using electrocardiogram gated radionuclide ventriculography].

Eighteen outpatients with chronic renal failure undergoing hemodialysis (HD) were studied. Immediately before and after HD, the left and right ventricular function measured by electrocardiogram gated radionuclide ventriculography (RNV). By HD, body weight changed 58.6 +/- 7.50 kg to 57.2 +/- 6.80 kg and BUN level changed 67.9 +/- 29.00 mg/dl to 37.1 +/- 18.96 mg/dl and creatinine level changed 11.3 +/- 3.90 mg/dl to 6.8 +/- 2.48 mg/dl. Before HD, cardiac output was 8.08 +/- 1.50 l/min and cardiac index was 5.00 +/- 0.87 l/(min m2). Left ventricular function improved (LVEF changed 60.4 +/- 6.85% to 64.2 +/- 8.7%, LVEF/LVET changed 0.237 +/- 0.048%/ms to 0.254 +/- 0.021%/ms) between before and after HD, but there was not significant difference. Right ventricular function improved (RVEF changed 41.2 +/- 8.00% to 50.0 +/- 11.96, RVEF/RVET changed 0.167 +/- 0.028%/ms to 0.209 +/- 0.059%/ms) between before and after HD, and there was significant difference (p less than 0.05).

Adult↗
PubMed1985

Effects of prostaglandin E1 infusion in the pre-operative management of critical congenital heart disease.

Prostaglandin E1 (PGE1) was administered to 27 infants in whom pulmonary or systemic blood flow was entirely or significantly dependent upon the patency of the ductus arteriosus. In 12 patients with pulmonary atresia or severe pulmonary stenosis, PGE1 infusion was followed by an improvement in hypoxemia and acidemia (group I). In 2 patients with left ventricular outflow-tract obstruction, PGE1 infusion was followed by an improvement in arterial blood pressure, peripheral perfusion and urine output (group II). In 5 patients with d-transposition of the great arteries and intact ventricular septum who had persistent severe hypoxemia after creation of an interatrial communication, PGE1 infusion improved the arterial oxygenation with dilatation of the ductus arteriosus (group III). Seven patients (3 of group I, 2 of group II and 2 of group III) failed to respond to PGE1. There were no fatal side effects. It is concluded that PGE1 therapy is highly effective in stabilizing pre-operative conditions of infants with ductus-dependent congenital heart disease.

Alprostadil↗
PubMed1985

[Adjusted relative survival rate and causes of death after resection of gastric cancer].

To estimate how many of 1,302 patients with curative resection of gastric cancer died of recurrence or other diseases, the cumulative survival rate (act), relative survival rate (rl) and adjusted relative survival rate (adj) were analyzed. Adj was computed excluding gastric cancer death, because the death rate of this disease can not be ignored in the Japanese population. The death rate from gastric cancer can be estimated by [1.0-(adj)] and that from other causes by [(adj)-(act)]. It is more appropriate to calculate adj for the patients with mucosal or submucosal cancer, and rl can be substituted for adj for those with deeper invasion.

Adult↗
PubMed1984

Correlation of lipolytic and lipogenic actions of synthetic peptides with structure.

The effects of various synthetic peptides on basal and ACTH-stimulated lipolysis in fat cells were examined. Glu-Arg-Gly-Phe-Phe-Phe possessed lipolytic activity and increased ACTH-stimulated lipolysis at concentrations higher than 0.5 mumol/ml. Glu-Arg-Gly-Phe-Phe-Tyr did not cause any release of FFA from fat cells. Glu-Arg-Gly-Leu-Leu-Leu had no lipolytic activity but inhibited ACTH-stimulated lipolysis at concentrations higher than 0.25 mumol/ml. Glu-Arg-Gly-Leu-Leu-Leu also inhibited epinephrine-stimulated lipolysis. The effects of the peptides on basal and insulin-stimulated lipogenesis in fat cells were examined. Glu-Arg-Gly-Phe-Phe-Tyr increased both basal and insulin-stimulated lipogenesis. A tripeptide, Glu-Arg-Gly, inhibited both basal and insulin-stimulated lipogenesis. Glu-Arg-Gly-Leu-Leu-Leu had no effect on either basal or insulin-stimulated lipogenesis. Glu-Arg-Gly-Phe-Phe-Phe and ACTH, which elicit FFA release from fat cells, also stimulated formation of [14C]triglyceride from [14C]glucose.

Adipose Tissue↗
PubMed1984

[Adjuvant chemotherapy after surgery in advanced gastric cancer].

Two hundred and fifty-four patients with advanced gastric cancer underwent radical surgery and ftorafur (FT) or 5-fluorouracil (5-FU) was orally administered as the adjuvant chemotherapy (ACT). Recurrence after ACT were analyzed by the quantification method II. As a result, it was found that: 1) ACT over 2 years could lower the recurrence rate, and careful follow-up is still necessary up to 4 years, and 2) after the remission induction therapy with mitomycin C and/or 5-FU and cytarabine, 12 mg/kg/day of FT for the first year and 8 mg for the second year are advisable.

Administration, Oral↗
PubMed1983

Effects of caffeine on pancreatic tumorigenesis by 4-hydroxyaminoquinoline 1-oxide in partially pancreatectomized rats.

The effects of caffeine on pancreatic tumorigenesis by 4-hydroxyaminoquinoline 1-oxide (4-HAQO) and on pancreatic DNA synthesis were studied in partially pancreatectomized male Wistar rats. 4-HAQO was injected i.v. as a single dose of 7 mg/kg body weight 3 days after partial pancreatectomy. Caffeine was injected s.c. every 12 h at the maximum tolerated dose (m.t.d.) of 120 mg/kg body weight, half the m.t.d., and one quarter the m.t.d. from 12 to 72 h before and 0 to 72, 72 to 132, and 0 to 132 h after 4-HAQO treatment. Post-treatment with caffeine from 0 to 132 h had a dose-dependent biphasic effect on pancreatic tumorigenesis: post-treatment with the m.t.d. of caffeine decreased the total number of nodules, whereas treatment with one quarter the m.t.d. of caffeine increased their number. Decrease in the number of nodules was also observed on post-treatment with the m.t.d. of caffeine from 0 to 72 or from 72 to 132 h. Pretreatment with the m.t.d. of caffeine had no significant effect on the number of nodules. Recovery of pancreatic DNA synthesis was slower after simultaneous treatment with the m.t.d. of caffeine and 4-HAQO than after treatment with 4-HAQO alone. The possible mechanism of the effect of caffeine on pancreatic tumorigenesis induced by 4-HAQO in rats is discussed.

4-Hydroxyaminoquinoline-1-oxide↗
PubMed1983

[Late results of coronary heart surgery. Late graft patency in coronary bypass procedure].

The graft patency was evaluated by a contrast enhanced computed tomography (CT) and/or digital subtraction angiography (DSA) in the follow up of aorto-coronary bypass surgery. One hundred and eighty-four patients included in this study received a total of 331 grafts. The Elipse S/200 Scanner for CT and Siemens Angiotron system for DSA were used for this study. Early in the study, selective coronary angiography were performed and the results were interpreted in 331 grafts and 86 grafts to evaluate the diagnostic reliability of CT and DSA for graft patency, respectively. While the CT scans correlated with angiographic assessment of graft patency showed 98% of sensitivity, 100% of specificity, and 98% of predicted accuracy, the DSA showed 95% of sensitivity, 100% of specificity and 95% of predicted accuracy, respectively. The patency rate in the early postoperative period was 94%, and the cumulative patency rate during follow up of 5 years was 93%, respectively. In summary, CT and DSA can provide useful information regarding graft patency in the long term follow up of aorto-coronary bypass surgery.

Adult↗